Cambridge: Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common ...
The news prompted a sell-off across the industry. In the US, shares in Pfizer sank more than 4% and Moderna were roughly 9% ...
The UK stock market experienced declines with significant impacts from AstraZeneca and GSK, contributing to the FTSE 100's ...
The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 ...
Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ETCompany ParticipantsEmma Walmsley - Chief ...
As head of HHS, Kennedy would lead a sprawling federal department that encompasses more than 100 programs supporting medicine ...
"Big Pharma" stocks took a tumble this morning following the news that President-elect Donald Trump has appointed Robert F.
Shares of drugmakers AstraZeneca dropped 2.4% and GSK dipped 3.2%, tracking losses in U.S. and European vaccine makers after ...
The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...